ArticleFrontiers in oncology2025
Efficacy and safety of high-intensity focused ultrasound ablation under general anesthesia in older hepatocellular carcinoma patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Older patients often have comorbidities, leading to a higher risk of delayed recovery while under general anesthesia. High-intensity focused ultrasound (HIFU) for patients with hepatocellular carcinoma (HCC) usually requires general anesthesia to alleviate procedure-related pain and ensure immobilization. This study aimed to evaluate the safety and efficacy of HIFU for the treatment of older patients with HCC, and to explore the associated prognosis and risk factors. Methods: A total of 174 patients with HCC who underwent HIFU were enrolled in this study and divided into three age groups: <60 years (n=100), 60-74 years (n=55), and ≥75 years (n=19). The risks of general anesthesia associated with HIFU were observed, and the ablation effects of HIFU were evaluated using contrast-enhanced CT or MRI. Survival analysis, prognosis and risk factors were analyzed. Results: The prevalence of comorbidities was 73.68%, 52.72%, and 26.00% in patients aged ≥75 years, 60-74 years, and <60 years, respectively. The difference between the three groups was significant ( Conclusions: HIFU ablation under general anesthesia for older HCC patients is safe, feasible and effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.